MS/Neuroimmunology

Clinical Research


fact_group

If you think you may qualify for one of these studies, please contact Neurology Research Partners at (303) 724-4644 or NeurologyResearchPartners@CUAnschutz.edu

 

 

COMIRB #Title (Please click on the title to see approved advertisement)Principal InvestigatorEligibility and InformationAdvertisement
21-3126The Evaluation Of Immune Responses To Sars-Cov-2 mRNA Vaccines In Multiple Sclerosis Patients On OcrelizumabAmanda Piquet, MDClinical TrialsSee Advertisement
12-0968Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological DisordersEnrique Alvarez, MD, PhDClinical TrialsN/A
18-1633Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)Enrique Alvarez, MD, PhDClinical TrialsN/A
17-1884Risk Factors in Early Multiple Sclerosis (RISE-MS)John Corboy, MDClinical TrialsSee Advertisement
19-0393Detection and Risk in Early MS (DREAMS)Teri Schreiner, MD, MPHN/ASee Advertisement
09-0952Rocky Mountain MS Center Tissue BankJohn Corboy, MDClinical TrialsN/A
19-1600An Observational Study Of Ocrelizumab Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies Amanda Piquet, MDN/ASee Advertisement
20-1000Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)Enrique Alvarez, MD, PhDClinical TrialsN/A
16-0156Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple SclerosisTeri Schreiner, MD, MPHClinical TrialsN/A
20-2153
Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions for Ocrelizumab Users: Measuring Patient Experiences and Safety Outcomes
Tim Vollmer, MD
Clinical TrialsSee Advertisement
19-1040A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Ocrelizumab Administration in Patients with Multiple SclerosisAmanda Piquet, MDClinical TrialsN/A
19-2525Lipoic Acid for the Treatment of Progressive Multiple SclerosisRobert Gross, MDClinical TrialsN/A
20-1569

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients with Relapsing-Remitting Multiple Sclerosis

Tim Vollmer, MDClinical TrialsSee Advertisement
20-0705A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl Fumarate or Fingolimod TherapyEnrique Alvarez, MD, PhDClinical TrialsN/A
20-0454A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis Enrique Alvarez, MD, PhDClinical TrialsN/A
20-0695Low Load Resistance Training Using Blood Flow Restriction for People with Multiple Sclerosis with Marked Mobility RestrictionMark Manago, DPT, PhD, PT, NCSClinical TrialsSee Advertisement
18-0179
Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery
Jeffrey Hebert, PT, PhD
Clinical Trials
See Advertisement
20-1527Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People with Multiple SclerosisMark Manago, DPT, PhD, PT, NCSClinical TrialsSee Advertisement